0001661181-21-000025.txt : 20210218 0001661181-21-000025.hdr.sgml : 20210218 20210218203413 ACCESSION NUMBER: 0001661181-21-000025 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210216 FILED AS OF DATE: 20210218 DATE AS OF CHANGE: 20210218 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gillheeney Gary S. CENTRAL INDEX KEY: 0001757373 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37906 FILM NUMBER: 21651645 MAIL ADDRESS: STREET 1: C/O ORGANOGENESIS INC. STREET 2: 85 DAN ROAD CITY: CANTON STATE: MA ZIP: 02021 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Organogenesis Holdings Inc. CENTRAL INDEX KEY: 0001661181 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 85 DAN ROAD CITY: CANTON STATE: MA ZIP: 02021 BUSINESS PHONE: 781-575-0775 MAIL ADDRESS: STREET 1: 85 DAN ROAD CITY: CANTON STATE: MA ZIP: 02021 FORMER COMPANY: FORMER CONFORMED NAME: Avista Healthcare Public Acquisition Corp. DATE OF NAME CHANGE: 20151215 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2021-02-16 0001661181 Organogenesis Holdings Inc. ORGO 0001757373 Gillheeney Gary S. C/O ORGANOGENESIS HOLDINGS INC. 85 DAN ROAD CANTON MA 02021 1 1 0 0 President and CEO Class A Common Stock 2021-02-16 4 A 0 51626 0 A 245845 D Class A Common Stock 2021-02-17 4 S 0 78201 13.3 D 167644 D Class A Common Stock 2021-02-17 4 S 0 11174 13.82 D 156470 D Class A Common Stock 2021-02-18 4 S 0 16663 12.85 D 139807 D Stock Option (Right to Buy) 13.68 2021-02-16 4 A 0 395289 0 A 2031-02-16 Class A Common Stock 395289 395289 D Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 16, 2021. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in August 2020. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $12.76 to $13.75, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $13.76 to $13.90, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $12.62 to $13.265, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. The option becomes exercisable in equal annual installments over four years beginning February 16, 2021. /s/ Stacie S. Aarestad, Attorney-in-Fact 2021-02-18